Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease.
Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.